Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
60Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-9.47M | $-0.63 |
| 2024 | $0.00 | $-8.29M | $-0.70 |
| 2023 | $0.00 | $-8.59M | $-0.74 |
| 2022 | $0.00 | $-8.11M | $-0.70 |
| 2021 | $0.00 | $-8.82M | $-0.81 |
Social Signal Score
Earnings
Wed, Sep 2(in 2 weeks)
Consensus estimate $-0.10 per share
Typical surprise +26.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, May 21$-0.10 vs $-0.13beat
- Tue, Feb 17$-0.11 vs $-0.14beat
- Fri, Nov 14$-0.10 vs $-0.18beat
- Mon, Sep 29$-0.13 vs $-0.20beat
- Thu, May 15$-0.14 vs $-0.19beat
- Fri, Feb 14$-0.14 vs $-0.18beat
Estimates and results for NNVC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
NNVChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsaccessnewswire.com·5d ago·Negative
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as
View source ↗